Novo Nordisk stock falls 1.04 percent as strategy doubts persist

Published on 09/30/2026 at 11:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 adjusted sales reached DKK 78.5 billion on August 4, 2026, up 7 percent at constant exchange rates. At Lang & Schwarz, Novo Nordisk stock was trading at EUR 33.46 on September 30, 2026, versus EUR 33.81 prior close.

Flatlay mit Spritze, Teststreifen, Notizbuch und Apfel auf weißem Untergrund — Novo Nordisk A/S (DK0062498333): Flatlay mit Spritze, Blutzucker-Teststreifen, Notizbuch und Apfel auf Weiß, Illustration mit AI erstellt.

Novo Nordisk stock (ISIN DK0062498333) was trading at EUR 33.46 at Lang & Schwarz on September 30, 2026 at 11:38 a.m. CEST, down 1.04 percent versus the prior close of EUR 33.81. The immediate backdrop is the company's September 21 strategy update, which pressured the shares as investors weighed its long-term growth ambitions against near-term uncertainty, according to Investing.com.

Strategy targets meet a cautious market

At the Capital Markets Day in London, Novo Nordisk said it aims for compound annual sales growth from 2026 to 2030 in line with industry peers and for a broadly stable adjusted operating margin. The company also outlined a risk-adjusted pipeline sales ambition above DKK 150 billion by 2035, while stressing that the targets are ambitions rather than financial guidance, Investing.com reported on September 21, 2026.

The scale of the pipeline is material: Novo plans to launch more than five medicines with potential blockbuster sales by 2030 and to expand capacity for oral GLP-1 treatments to serve 10 times more people with obesity. That ambition gives the stock a longer-term growth narrative, but it does not remove the need to prove execution.

Q2 growth came with a profit gap

Novo Nordisk's Q2 2026 results were announced on August 4, 2026, according to the company's financial-results calendar. Adjusted sales reached DKK 78.5 billion, up 7 percent at constant exchange rates, while adjusted operating profit rose 11 percent at constant exchange rates, Beancount reported.

Net income was DKK 20.99 billion in Q2 2026, compared with DKK 48.56 billion in Q1 2026. The comparison shows why sales growth alone is not enough to settle the market debate: profitability and pricing remain central to the investment case.

Jefferies lowers its target

Jefferies retained its Hold rating but cut its Novo Nordisk price target from DKK 285 to DKK 275 on September 21, 2026. The bank said the strategy day had not reduced uncertainty ahead of semaglutide's patent expiry, according to MarketScreener.

November 4 is the next checkpoint

Novo Nordisk is scheduled to announce its first three quarters of 2026 on November 4, 2026 at 7:30 a.m. CEST, according to its investor calendar. For investors, that report will put the strategy promises against fresh evidence on sales, margins and demand for obesity treatments.

Stock trades lower in intraday trading

Novo Nordisk stock was trading at EUR 33.46 at Lang & Schwarz on September 30, 2026 at 11:38 a.m. CEST, down 1.04 percent versus the prior close of EUR 33.81. The Class B shares are listed on Nasdaq Copenhagen under ticker NOVO B.